Loading...
XNASBPTH
Market cap4mUSD
Dec 24, Last price  
1.04USD
1D
-6.31%
1Q
13.18%
Jan 2017
-99.98%
IPO
-99.98%
Name

Bio Path Holdings Inc

Chart & Performance

D1W1MN
XNAS:BPTH chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-4.35%
Rev. gr., 5y
100.00%
Revenues
0k
79,31359,45343,81218,4380000000013,00037,000000000
Net income
-16m
L+16.21%
-66,270-84,538-147,909-52,546-2,852,767-1,969,738-2,081,500-2,363,344-2,582,537-3,266,013-4,519,949-5,466,794-6,750,000-7,023,000-8,583,000-8,505,000-10,856,000-10,437,000-13,835,000-16,078,000
CFO
-12m
L-23.62%
-45,515-54,964-101,756-64,913-930,600-1,567,446-1,148,156-1,149,911-1,993,404-2,313,160-3,817,497-5,004,291-8,148,000-7,957,000-6,124,000-8,361,000-10,960,000-9,917,000-15,103,000-11,535,000
Earnings
Mar 06, 2025

Profile

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
URL
https://www.biopathholdings.com/
IPO date
Jan 11, 2006
Employees
10
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
16,021
14,079
10,604
Unusual Expense (Income)
NOPBT
(16,021)
(14,079)
(10,604)
NOPBT Margin
Operating Taxes
(33)
(3)
Tax Rate
NOPAT
(16,021)
(14,046)
(10,601)
Net income
(16,078)
16.21%
(13,835)
32.56%
(10,437)
-3.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,677
1,734
15,849
BB yield
-757.75%
-315.65%
-1,250.25%
Debt
Debt current
206
108
82
Long-term debt
123
334
388
Deferred revenue
Other long-term liabilities
863
Net debt
(723)
(9,942)
(23,304)
Cash flow
Cash from operating activities
(11,535)
(15,103)
(9,917)
CAPEX
(21)
(70)
Cash from investing activities
(21)
(70)
Cash from financing activities
2,203
1,734
20,006
FCF
(12,478)
(16,139)
(10,873)
Balance
Cash
1,052
10,384
23,774
Long term investments
Excess cash
1,052
10,384
23,774
Stockholders' equity
(107,606)
(91,521)
(77,654)
Invested Capital
109,126
105,916
103,346
ROIC
ROCE
EV
Common stock shares outstanding
478
364
336
Price
0.46
-69.34%
1.51
-59.95%
3.77
7.71%
Market cap
221
-59.71%
549
-56.67%
1,268
88.30%
EV
(502)
(9,393)
(22,036)
EBITDA
(15,843)
(13,901)
(10,443)
EV/EBITDA
0.03
0.68
2.11
Interest
33
Interest/NOPBT